TickerSparkInvestor Intelligence
TickerSparkInvestor Intelligence
Custom Reports
Stock Deep Dives · Free to Try
AI Analyst
Agentic Chat · Free to Try
Watchlist
Track Your Stocks · Free
Spark Charts
AI Technical Analysis · Free to Try
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio · Pro
My Portfolio
Brokerage Connected · Pro
Custom Reports
Stock Deep Dives
AI Analyst
Agentic Chat
Watchlist
Your Stocks & Notes
Spark Charts
AI Technical Analysis
Trade Tracker
AI-Managed Portfolio
My Portfolio
Brokerage Connected
Main Feed
Today's Market Intel
Stock Reports
AI Research Reports
Top Stocks
AI-Curated Stock Lists
Commentary
Opinionated Stock Takes
Stock Teasers
The Stock Behind the Promo
Trending Stocks
Today's Big Movers
Earnings Coverage
Flashes & Deep Dives
Macro Updates
Economy & Markets
IPO Calendar
Upcoming Listings
CommunityDashboard
Log inCreate Account
← Back to TickerSpark
▌Earnings Flash·August 4, 2026

IDEXX Laboratories, Inc. (IDXX) gains on earnings beats

IDEXX Laboratories, Inc. (IDXX) gains 3.7% after reporting earnings beats, as investors react positively to stronger-than-expected results and improved outlook.

Earnings FlashIDXXHealthcareMedical - Diagnostics & Research
By TickerSpark·August 4, 2026·2 min read
IDEXX Laboratories, Inc. (IDXX) gains on earnings beats
▌Key Takeaway
IDEXX Laboratories, Inc. (IDXX) reported a clean earnings beat, with EPS of $4.27 versus $3.94 expected and revenue of $1.22 billion versus $1.20 billion expected. Shares rose 3.67% as investors rewarded the company’s fifth straight quarter of topping EPS estimates, signaling continued execution strength and supporting the stock’s positive momentum.

IDEXX Laboratories, Inc. (IDXX) Earnings Beat, Gains

IDEXX Laboratories, Inc. (IDXX) beat estimates on both EPS and revenue, while the stock gained 3.67% in regular-session trading to $588.68.

Key Numbers

  • EPS: $4.27 versus the $3.94 estimate, a beat.

§ Product

  • How It Works
  • Custom Reports
  • AI Analyst
  • Intel Dashboard
  • Spark Charts
  • Trade Tracker
  • My Portfolio
  • Plans

§ Research

  • Main Feed
  • Community
  • Stock Reports
  • Macro Updates
  • Blog

§ Company

  • About Us
  • Contact

§ Fine Print

  • Terms of Service
  • Privacy Policy
  • Full Disclaimer
  • Cookie Policy

Notice: All content and data on TickerSpark is for informational purposes only and does not constitute financial or investment advice. All investments involve risk. Please see our Full Disclaimer for more details.

© 2026 Maxwell Cyberlogic LLC

Not Investment Advice

Made in Delaware, USA

Revenue: $1.22B versus the $1.20B estimate, a beat.
  • Stock reaction: IDXX closed at $588.68, up 3.67% from the prior close of $567.84.
  • Regular-session range: $584.58 to $621.83.
  • EPS trend: IDXX topped estimates in each of the five quarters listed.

    • A Fifth Straight EPS Beat Raises the Execution Bar

    The dual beat gives IDXX a clean quarterly scorecard. Profit and sales both cleared estimates, offering investors evidence of stronger-than-forecast quarterly execution.

    The more durable signal is the pattern. EPS topped estimates in all five listed quarters, rising from $3.63 versus $3.28 on Aug. 4, 2025, to $4.27 versus $3.94 in the latest quarter. That consistency raises the standard for future results: another beat would reinforce repeatability, while a miss would break the streak.

    The market rewarded the result, but trading volume remained below average. IDXX gained 3.67% on 479,780 shares, compared with an average volume of 644,159 shares, leaving the stock's follow-through important after the initial gains.

    Bottom line: IDXX delivered a clean EPS and revenue beat, and its five-quarter EPS streak supports the stock's positive reaction.

    Read the full IDXX research report
    ▌Common Questions

    Frequently asked questions

    +Did IDEXX Laboratories (IDXX) beat earnings this quarter?
    Yes. IDEXX Laboratories reported EPS of $4.27 versus the $3.94 estimate and revenue of $1.22 billion versus the $1.20 billion estimate. The company beat estimates on both profit and sales.
    +Why did IDXX stock rise after earnings?
    IDXX gained 3.67% because the company delivered a clean earnings beat on both EPS and revenue. Investors also reacted positively to the fact that this was the fifth straight quarter in which IDEXX topped EPS estimates.
    +How strong was IDEXX Laboratories' earnings streak?
    IDEXX topped EPS estimates in each of the five quarters listed in the article. The latest quarter showed EPS of $4.27 versus $3.94 expected, extending that streak.
    +What was the market reaction to IDEXX Laboratories' earnings report?
    Shares of IDEXX Laboratories closed at $588.68, up 3.67% from the prior close of $567.84. The stock traded between $584.58 and $621.83 during the regular session, but volume was below average at 479,780 shares versus a 644,159-share average.
    ▌The Daily Briefing · Free

    A new stock idea, every evening.

    One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.

    Daily market recap + weekly preview. One-click unsubscribe in every email.

    ▌The Full Report

    Want the full picture on IDXX?

    The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.

    Read the IDXX report →Get Full Access →

    Not ready to subscribe? ·

    ▌The Full Report

    Get the full IDXX research report

    • Analyst-grade deep dive
    • Charts, valuation, grades
    • Buy/sell price targets
    Read the IDXX report →
    ▌For Active Investors

    Smarter research, on every ticker

    • Daily market intelligence
    • On-demand stock analysis
    • AI analyst chat
    Get Full Access →

    Cancel anytime

    ▌The Daily Briefing · Free

    A new stock idea, every evening.

    One stock worth watching each weekday, free in your inbox.

    Daily market recap + weekly preview. One-click unsubscribe in every email.

    ▌More on IDXX

    More to read

    All articles
    IDEXX Laboratories, Inc. (IDXX) gains on deep earnings analysis
    IDXX

    IDEXX Laboratories, Inc. (IDXX) gains on deep earnings analysis

    IDEXX Laboratories, Inc. (IDXX) gains after a Q2 beat, but the real story is in the details: recurring diagnostics growth, margin expansion, and a raised 2026 outlook. This deep-dive breaks down segment performance, pricing, instrument trends, and what the guidance implies for the stock.

    Aug 4·7 min
    IDEXX Laboratories (IDXX): Recurring Diagnostics Drive the Buy Case
    IDXX

    IDEXX Laboratories (IDXX): Recurring Diagnostics Drive the Buy Case

    IDEXX delivered strong Q1 growth on the back of recurring diagnostics, premium instrument placements, and high customer retention. The stock still looks expensive, but the installed-base flywheel and raised 2026 guidance support a Buy.

    Aug 4·20 min
    Gilead Sciences (GILD): HIV Momentum Drives a Buy Case
    GILD

    Gilead Sciences (GILD): HIV Momentum Drives a Buy Case

    Gilead’s HIV franchise is accelerating, with Yeztugo, Trodelvy, and a stronger pipeline offsetting pressure in Veklury and cell therapy. The stock looks attractive for moderate-risk investors with a medium-term horizon.

    Aug 4·18 min